Many studies have been performed to explore the combined effects of GSTM1 present/null and CYP1A1 MspI polymorphisms with lung cancer (LC) risk, but the results are contradictory. Two previous meta-analyses have been reported on the issue in 2011 and 2014. However, several new articles have since been published. In addition, their meta-analyses did not valuate the credibility of significantly positive results. Objectives. We performed an updated meta-analysis to solve the controversy following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline .

中文翻译：

---

GSTM1当前/无效和CYP1A1 MspI多态性与肺癌风险之间的联合作用与肺癌风险的关联：一项最新的荟萃分析。

已经进行了许多研究以探讨GSTM1存在/无效和CYP1A1 MspI多态性与肺癌（LC）风险的组合作用，但结果相矛盾。之前在2011年和2014年对该问题进行过两次荟萃分析。但是，此后发表了几篇新文章。此外，他们的荟萃分析未评估明显阳性结果的可信度。目标。我们按照“系统评价和荟萃分析的首选报告项目”指南进行了更新的荟萃分析，以解决这一争议。